Stereotaxis, Inc. (NYSEAMERICAN:STXS – Get Rating) Director Paul J. Isaac bought 28,738 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were acquired at an average cost of $1.82 per share, with a total value of $52,303.16. Following the purchase, the director now directly owns 2,430,441 shares of the company’s stock, valued at $4,423,402.62. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of NYSEAMERICAN:STXS traded down $0.03 during mid-day trading on Thursday, hitting $1.75. 329,896 shares of the company traded hands, compared to its average volume of 333,076. The stock has a market cap of $130.66 million, a price-to-earnings ratio of -8.75 and a beta of 1.74. Stereotaxis, Inc. has a 12-month low of $1.72 and a 12-month high of $10.30.
Stereotaxis (NYSEAMERICAN:STXS – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Stereotaxis had a negative return on equity of 38.69% and a negative net margin of 39.69%. As a group, analysts anticipate that Stereotaxis, Inc. will post -0.2 earnings per share for the current year.
Several large investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in Stereotaxis during the third quarter worth $56,000. Principal Financial Group Inc. bought a new stake in Stereotaxis during the third quarter worth $57,000. Wellington Shields & Co. LLC bought a new stake in Stereotaxis during the first quarter worth $58,000. OLD Mission Capital LLC bought a new stake in Stereotaxis during the third quarter worth $61,000. Finally, ProShare Advisors LLC bought a new stake in Stereotaxis during the fourth quarter worth $67,000. 56.84% of the stock is currently owned by institutional investors.
Stereotaxis Company Profile (Get Rating)
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
- Get a free copy of the StockNews.com research report on Stereotaxis (STXS)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.